Tag Archives: Prometheus v. Mayo

Prometheus Q/A Results: Does Patent Eligibility Impact Biotech Research?

Posted on May 7, 2012 by Warren Woessner

A guest post from shareholder Robin Chadwick of SLW. A quick survey of folks who read this blog indicates that funding for 5 Buy Cheap Cialis Soft 0% of respondents’ R&D is affected by whether or not a project was … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , | Leave a comment

PTO To Biotech Examiners – We’ll Get Back To You!

Posted on March 26, 2012 by Warren Woessner

On March 21, 2012, Andrew H Hirschfield, Associate Commissioner for Patent Examination Policy, sent a short memo to the Patent Examining Corps to inform them about the decision in Prometheus v. Mayo. The “preliminary guidance” that was provided included a … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , | Leave a comment

Unnatural Acts – Patenting Diagnostic Tests Post-Prometheus

Posted on March 23, 2012 by Warren Woessner

The US Supreme Court case of Mayo v. Prometheus has generated a lot of interest precisely because it clouds the future of patent claims to diagnostic methodologies in general and to ‘personalized medicine’ in specific. The decision is likely to … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , | 1 Comment

Myriad Revisited – The Consequences of Prometheus Unbound

Posted on March 22, 2012 by Warren Woessner

In my last post on Prometheus, I concluded: It is hard to think of a diagnostic assay claim that does not either detect the +/- presence of a marker (like anti-HIV antibodies) or involve the comparison of the level of … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , | Leave a comment